We have signed a licencing agreement w Balanced Biotech – the American biotech company. Together they will create a revolutionary treatment for breast cancer.
The licencing agreement between the companies is valued at several million USD. As of 2018 the market for breast-cancer treatments was valued at 13.4B USD – by 2021 that figure is expected to increase to 17.2B USD. Biotts is developing carriers of medicinal substances. The technology has the potential to be utilized as a method of transport for popular oncological, anti-inflammatory and pain medications. More here (in polish).